Treatment of alpha and beta herpesvirus infections in solid organ transplant recipients

References

• Zuckerman RA, Limaye AP. Varicella zoster virus (VZV) and herpes simplex virus (HSV) in solid organ transplant patients. Am J Transplant. 2013;13 Suppl 3:55–66; quiz 66.
   PubMed Web of Science ®Google Scholar
• Shiley K, Blumberg E. Herpes viruses in transplant recipients: HSV, VZV, human herpes viruses, and EBV. Hematol Oncol Clin North Am. 2011;25(1):171–191.
   PubMed Web of Science ®Google Scholar
• Miller GG, Dummer JS. Herpes simplex and varicella zoster viruses: forgotten but not gone. Am J Transplant. 2007;7(4):741–747.
   PubMed Web of Science ®Google Scholar
• Schillinger JA, Xu F, Sternberg MR, et al. National seroprevalence and trends in herpes simplex virus type 1 in the United States, 1976-1994. Sex Transm Dis. 2004;31(12):753–760.
   PubMed Web of Science ®Google Scholar
• Fleming DT, McQuillan GM, Johnson RE, et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med. 1997;337(16):1105–1111.
   PubMed Web of Science ®Google Scholar
• Xu F, Sternberg MR, Kottiri BJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA. 2006;296(8):964–973.
   PubMed Web of Science ®Google Scholar
• Wilck MB, Zuckerman RA. Herpes simplex virus in solid organ transplantation. Am J Transplant. 2013;13 Suppl 4:121–127.
   PubMed Web of Science ®Google Scholar
• Naraqi S, Jackson GG, Jonasson O, et al. Prospective study of prevalence, incidence, and source of herpesvirus infections in patients with renal allografts. J Infect Dis. 1977;136(4):531–540.
   PubMed Web of Science ®Google Scholar
• Singh N, Dummer JS, Kusne S, et al. Infections with cytomegalovirus and other herpesviruses in 121 liver transplant recipients: transmission by donated organ and the effect of OKT3 antibodies. J Infect Dis. 1988;158(1):124–131.
   PubMed Web of Science ®Google Scholar
• Smyth RL, Higenbottam TW, Scott JP, et al. Herpes simplex virus infection in heart-lung transplant recipients. Transplantation. 1990;49(4):735–739.
   PubMed Web of Science ®Google Scholar
• Pettersson E, Hovi T, Ahonen J, et al. Prophylactic oral acyclovir after renal transplantation. Transplantation. 1985;39(3):279–281.
   PubMed Web of Science ®Google Scholar
• Seale L, Jones CJ, Kathpalia S, et al. Prevention of herpesvirus infections in renal allograft recipients by low-dose oral acyclovir. JAMA. 1985;254(24):3435–3438.
   PubMed Web of Science ®Google Scholar
• Razonable RR. Management of viral infections in solid organ transplant recipients. Expert Rev Anti Infect Ther. 2011;9(6):685–700.
   PubMed Web of Science ®Google Scholar
• Piret J, Boivin G. Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. Antimicrob Agents Chemother. 2011;55(2):459–472.
   PubMed Web of Science ®Google Scholar
• Langston AA, Redei I, Caliendo AM, et al. Development of drug-resistant herpes simplex virus infection after haploidentical hematopoietic progenitor cell transplantation. Blood. 2002;99(3):1085–1088.
   PubMed Web of Science ®Google Scholar
• Nichols WG, Boeckh M, Carter RA, et al. Transferred herpes simplex virus immunity after stem-cell transplantation: clinical implications. J Infect Dis. 2003;187(5):801–808.
   PubMed Web of Science ®Google Scholar
• Schulte EC, Sauerbrei A, Hoffmann D, et al. Acyclovir resistance in herpes simplex encephalitis. Ann Neurol. 2010;67(6):830–833.
   PubMed Web of Science ®Google Scholar
• Malvy D, Treilhaud M, Bouee S, et al. A retrospective, case-control study of acyclovir resistance in herpes simplex virus. Clin Infect Dis. 2005;41(3):320–326.
   PubMed Web of Science ®Google Scholar
• Fishman JA. Overview: cytomegalovirus and the herpesviruses in transplantation. Am J Transplant. 2013;13 Suppl 3:1–8; quiz 8.
   PubMed Web of Science ®Google Scholar
• Alcaide ML, Abbo L, Pano JR, et al. Herpes zoster infection after liver transplantation in patients receiving induction therapy with alemtuzumab. Clin Transplant. 2008;22(4):502–507.
   PubMed Web of Science ®Google Scholar
• Arness T, Pedersen R, Dierkhising R, et al. Varicella zoster virus-associated disease in adult kidney transplant recipients: incidence and risk-factor analysis. Transpl Infect Dis. 2008;10(4):260–268.
   PubMed Web of Science ®Google Scholar
• Manuel O, Kumar D, Singer LG, et al. Incidence and clinical characteristics of herpes zoster after lung transplantation. J Heart Lung Transplant. 2008;27(1):11–16.
   PubMed Web of Science ®Google Scholar
• Herrero JI, Quiroga J, Sangro B, et al. Herpes zoster after liver transplantation: incidence, risk factors, and complications. Liver Transpl. 2004;10(9):1140–1143.
   PubMed Web of Science ®Google Scholar
• Levitsky J, Kalil A, Meza JL, et al. Herpes zoster infection after liver transplantation: a case-control study. Liver Transpl. 2005;11(3):320–325.
   PubMed Web of Science ®Google Scholar
• Gourishankar S, McDermid JC, Jhangri GS, et al. Herpes zoster infection following solid organ transplantation: incidence, risk factors and outcomes in the current immunosuppressive era. Am J Transplant. 2004;4(1):108–115.
   PubMed Web of Science ®Google Scholar
• Griffiths P, Whitley R, Snydman DR, et al. Contemporary management of cytomegalovirus infection in transplant recipients: guidelines from an IHMF workshop, 2007. Herpes. 2008;15(1):4–12.
   PubMedGoogle Scholar
• Razonable RR. Epidemiology of cytomegalovirus disease in solid organ and hematopoietic stem cell transplant recipients. Am J Health Syst Pharm. 2005;62(8 Suppl 1):S7–13.
   Google Scholar
• Razonable RR, Emery VC. Management of CMV infection and disease in transplant patients. 27-29 February 2004. Herpes. 2004;11(3):77–86.
   PubMedGoogle Scholar
• Betts RF, Hanshaw JB. Cytomegalovirus (CMV) in the compromised host(s). Annu Rev Med. 1977;28:103–110.
   PubMed Web of Science ®Google Scholar
• Razonable RR, Rivero A, Rodriguez A, et al. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J Infect Dis. 2001;184(11):1461–1464.
   PubMed Web of Science ®Google Scholar
• Isada CM, Yen-Lieberman B, Lurain NS, et al. Clinical characteristics of 13 solid organ transplant recipients with ganciclovir-resistant cytomegalovirus infection. Transpl Infect Dis. 2002;4(4):189–194.
   PubMedGoogle Scholar
• Kruger RM, Shannon WD, Arens MQ, et al. The impact of ganciclovir-resistant cytomegalovirus infection after lung transplantation. Transplantation. 1999;68(9):1272–1279.
   PubMed Web of Science ®Google Scholar
• Lautenschlager I, Razonable RR. Human herpesvirus-6 infections in kidney, liver, lung, and heart transplantation: review. Transpl Int. 2012;25(5):493–502.
   PubMed Web of Science ®Google Scholar
• Razonable RR. Human herpesviruses 6, 7 and 8 in solid organ transplant recipients. Am J Transplant. 2013;13 Suppl 3:67–77; quiz 77–68.
   PubMed Web of Science ®Google Scholar
• Delbridge MS, Karim MS, Shrestha BM, et al. Colitis in a renal transplant patient with human herpesvirus-6 infection. Transpl Infect Dis. 2006;8(4):226–228.
   PubMed Web of Science ®Google Scholar
• Nash PJ, Avery RK, Tang WH, et al. Encephalitis owing to human herpesvirus-6 after cardiac transplant. Am J Transplant. 2004;4(7):1200–1203.
   PubMed Web of Science ®Google Scholar
• Singh N, Carrigan DR, Gayowski T, et al. Variant B human herpesvirus-6 associated febrile dermatosis with thrombocytopenia and encephalopathy in a liver transplant recipient. Transplantation. 1995;60(11):1355–1357.
   PubMed Web of Science ®Google Scholar
• Vinnard C, Barton T, Jerud E, et al. A report of human herpesvirus 6-associated encephalitis in a solid organ transplant recipient and a review of previously published cases. Liver Transpl. 2009;15(10):1242–1246.
   PubMed Web of Science ®Google Scholar
• Lee SO, Brown RA, Eid AJ, et al. Chromosomally integrated human herpesvirus-6 in kidney transplant recipients. Nephrol Dial Transplant. 2011;26(7):2391–2393.
   PubMed Web of Science ®Google Scholar
• Lee SO, Brown RA, Razonable RR. Clinical significance of pretransplant chromosomally integrated human herpesvirus-6 in liver transplant recipients. Transplantation. 2011;92(2):224–229.
   PubMed Web of Science ®Google Scholar
• Lee SO, Brown RA, Razonable RR. Chromosomally integrated human herpesvirus-6 in transplant recipients. Transpl Infect Dis. 2012;14(4):346–354.
   PubMed Web of Science ®Google Scholar
• Pellett PE, Ablashi DV, Ambros PF, et al. Chromosomally integrated human herpesvirus 6: questions and answers. Rev Med Virol. 2012;22(3):144–155.
   PubMed Web of Science ®Google Scholar
• Anton A, Cervera C, Pumarola T, et al. Human herpesvirus 7 primary infection in kidney transplant recipients. Transplantation. 2008;85(2):298–302.
   PubMed Web of Science ®Google Scholar
• Razonable RR, Zerr DM. HHV-6, HHV-7 and HHV-8 in solid organ transplant recipients. Am J Transplant. 2009;9 Suppl 4:S97–100.
   Google Scholar
• Razonable RR, Paya CV. The impact of human herpesvirus-6 and −7 infection on the outcome of liver transplantation. Liver Transpl. 2002;8(8):651–658.
   PubMed Web of Science ®Google Scholar
• Baldwin K. Ganciclovir-resistant human herpesvirus-6 encephalitis in a liver transplant patient: a case report. J Neurovirol. 2011;17(2):193–195.
   PubMed Web of Science ®Google Scholar
• Bounaadja L, Piret J, Goyette N, et al. Analysis of HHV-6 mutations in solid organ transplant recipients at the onset of cytomegalovirus disease and following treatment with intravenous ganciclovir or oral valganciclovir. J Clin Virol. 2013;58(1):279–282.
   PubMed Web of Science ®Google Scholar
• Ljungman P. Prophylaxis against herpesvirus infections in transplant recipients. Drugs. 2001;61(2):187–196.
   PubMed Web of Science ®Google Scholar
• Ashley RL, Corey L. Effect of acyclovir treatment of primary genital herpes on the antibody response to herpes simplex virus. J Clin Invest. 1984;73(3):681–688.
   PubMed Web of Science ®Google Scholar
• Nilsen AE, Aasen T, Halsos AM, et al. Efficacy of oral acyclovir in the treatment of initial and recurrent genital herpes. Lancet. 1982;2(8298):571–573.
   PubMed Web of Science ®Google Scholar
• Serota FT, Starr SE, Bryan CK, et al. Acyclovir treatment of herpes zoster infections. Use in children undergoing bone marrow transplantation. JAMA. 1982;247(15):2132–2135.
   PubMed Web of Science ®Google Scholar
• Wagstaff AJ, Faulds D, Goa KL. Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1994;47(1):153–205.
   PubMed Web of Science ®Google Scholar
• Razonable RR. Antiviral drugs for viruses other than human immunodeficiency virus. Mayo Clin Proc. 2011;86(10):1009–1026.
   PubMed Web of Science ®Google Scholar
• Lurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev. 2010;23(4):689–712.
   Google Scholar
• Elion GB. Mechanism of action and selectivity of acyclovir. Am J Med. 1982;73(1a):7–13.
   PubMed Web of Science ®Google Scholar
• Jiang J, Zhu Y, Jian G, et al. Randomized case-controlled trial of oral low-dose acyclovir for prevention of virus infections in recipients of renal allografts. Chin Med J (Engl). 1995;108(6):459–461.
   PubMed Web of Science ®Google Scholar
• Jirasiritham S, Sumethkul V, Chiewsilp P, et al. Prevention of recurrent herpes infection after renal transplantation by low-dose oral acyclovir. Transplant Proc. 1994;26(4):2125–2126.
   PubMed Web of Science ®Google Scholar
• Schlech WF 3rd, Meagher N, Cohen AD, et al. A randomized double-blind placebo controlled trial of oral acyclovir in renal allograft recipients. Can J Infect Dis. 1993;4(2):84–88.
   PubMedGoogle Scholar
• Stoffel M, Squifflet JP, Pirson Y, et al. Effectiveness of oral acyclovir prophylaxis in renal transplant recipients. Transplant Proc. 1987;19(1 Pt 3):2190–2193.
   PubMed Web of Science ®Google Scholar
• Tang IY, Maddux MS, Veremis SA, et al. Low-dose oral acyclovir for prevention of herpes simplex virus infection during OKT3 therapy. Transplant Proc. 1989;21(1 Pt 2):1758–1760.
   PubMed Web of Science ®Google Scholar
• Arazi HC, Delgado D, Carosella V, et al. Prevention of symptomatic infection by herpesvirus in patients after heart transplantation. Transplant Proc. 1999;31(6):2530.
   PubMed Web of Science ®Google Scholar
• Carrier M, Pelletier GB, Cartier R, et al. Prevention of herpes simplex virus infection by oral acyclovir after cardiac transplantation. Can J Surg. 1992;35(5):513–516.
   PubMed Web of Science ®Google Scholar
• Barkholt L, Lewensohn-Fuchs I, Ericzon BG, et al. High-dose acyclovir prophylaxis reduces cytomegalovirus disease in liver transplant patients. Transpl Infect Dis. 1999;1(2):89–97.
   PubMedGoogle Scholar
• De Clercq E. Antivirals for the treatment of herpesvirus infections. J Antimicrob Chemother. 1993;32 Suppl A:121–132.
   PubMed Web of Science ®Google Scholar
• Bean B, Aeppli D. Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster. J Infect Dis. 1985;151(2):362–365.
   PubMed Web of Science ®Google Scholar
• Perazella MA. Crystal-induced acute renal failure. Am J Med. 1999;106(4):459–465.
   PubMed Web of Science ®Google Scholar
• Ernst ME, Franey RJ. Acyclovir- and ganciclovir-induced neurotoxicity. Ann Pharmacother. 1998;32(1):111–113.
   PubMed Web of Science ®Google Scholar
• Hellden A, Lycke J, Vander T, et al. The aciclovir metabolite CMMG is detectable in the CSF of subjects with neuropsychiatric symptoms during aciclovir and valaciclovir treatment. J Antimicrob Chemother. 2006;57(5):945–949.
   PubMed Web of Science ®Google Scholar
• Bacon TH, Levin MJ, Leary JJ, et al. Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin Microbiol Rev. 2003;16(1):114–128.
   PubMed Web of Science ®Google Scholar
• Gateley A, Gander RM, Johnson PC, et al. Herpes simplex virus type 2 meningoencephalitis resistant to acyclovir in a patient with AIDS. J Infect Dis. 1990;161(4):711–715.
   PubMed Web of Science ®Google Scholar
• Levin MJ, Bacon TH, Leary JJ. Resistance of herpes simplex virus infections to nucleoside analogues in HIV-infected patients. Clin Infect Dis. 2004;39 Suppl 5:S248–257.
   Google Scholar
• Ljungman P, Ellis MN, Hackman RC, et al. Acyclovir-resistant herpes simplex virus causing pneumonia after marrow transplantation. J Infect Dis. 1990;162(1):244–248.
   PubMed Web of Science ®Google Scholar
• Weller S, Blum MR, Doucette M, et al. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin Pharmacol Ther. 1993;54(6):595–605.
   PubMed Web of Science ®Google Scholar
• Acosta EP, Fletcher CV. Valacyclovir. Ann Pharmacother. 1997;31(2):185–191.
   PubMed Web of Science ®Google Scholar
• Lowance D, Neumayer HH, Legendre CM, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med. 1999;340(19):1462–1470.
   PubMed Web of Science ®Google Scholar
• Gupta R, Warren T, Wald A. Genital herpes. Lancet. 2007;370(9605):2127–2137.
   PubMed Web of Science ®Google Scholar
• Spruance SL, Tyring SK, DeGregorio B, et al. A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Valaciclovir HSV Study Group. Arch Intern Med. 1996;156(15):1729–1735.
   PubMedGoogle Scholar
• Pergam SA, Limaye AP. Varicella zoster virus in solid organ transplantation. Am J Transplant. 2013;13 Suppl 4:138–146.
   PubMed Web of Science ®Google Scholar
• Pavlopoulou ID, Syriopoulou VP, Chelioti H, et al. A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients. Clin Microbiol Infect. 2005;11(9):736–743.
   PubMed Web of Science ®Google Scholar
• Reischig T, Jindra P, Mares J, et al. Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection. Transplantation. 2005;79(3):317–324.
   PubMed Web of Science ®Google Scholar
• Reischig T, Opatrny K Jr., Bouda M, et al. A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation. Transpl Int. 2002;15(12):615–622.
   PubMed Web of Science ®Google Scholar
• Reischig T, Jindra P, Hes O, et al. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am J Transplant. 2008;8(1):69–77.
   PubMed Web of Science ®Google Scholar
• Kacer M, Kielberger L, Bouda M, et al. Valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus: an economic perspective. Transpl Infect Dis. 2015;17(3):334–341.
   PubMed Web of Science ®Google Scholar
• Egan JJ, Carroll KB, Yonan N, et al. Valacyclovir prevention of cytomegalovirus reactivation after heart transplantation: a randomized trial. J Heart Lung Transplant. 2002;21(4):460–466.
   PubMed Web of Science ®Google Scholar
• Kimberlin DW, Whitley RJ. Antiviral therapy of HSV-1 and −2. In: Arvin A, Campadelli-Fiume G, Mocarski E, editors. Human herpesviruses: biology, therapy, and immunoprophylaxis. Cambridge: Cambridge University Press; 2007.
   Google Scholar
• Gill KS, Wood MJ. The clinical pharmacokinetics of famciclovir. Clin Pharmacokinet. 1996;31(1):1–8.
   PubMed Web of Science ®Google Scholar
• Faro S. A review of famciclovir in the management of genital herpes. Infect Dis Obstet Gynecol. 1998;6(1):38–43.
   PubMedGoogle Scholar
• Chacko M, Weinberg JM. Famciclovir for cutaneous herpesvirus infections: an update and review of new single-day dosing indications. Cutis. 2007;80(1):77–81.
   PubMed Web of Science ®Google Scholar
• Tyring S, Belanger R, Bezwoda W, et al. A randomized, double-blind trial of famciclovir versus acyclovir for the treatment of localized dermatomal herpes zoster in immunocompromised patients. Cancer Invest. 2001;19(1):13–22.
   PubMed Web of Science ®Google Scholar
• Saltzman R, Jurewicz R, Boon R. Safety of famciclovir in patients with herpes zoster and genital herpes. Antimicrob Agents Chemother. 1994;38(10):2454–2457.
   PubMed Web of Science ®Google Scholar
• Fletcher C, Sawchuk R, Chinnock B, et al. Human pharmacokinetics of the antiviral drug DHPG. Clin Pharmacol Ther. 1986;40(3):281–286.
   PubMed Web of Science ®Google Scholar
• Nichols WG, Boeckh M. Recent advances in the therapy and prevention of CMV infections. J Clin Virol. 2000;16(1):25–40.
   PubMed Web of Science ®Google Scholar
• Griffiths PD, Boeckh M. Antiviral therapy for human cytomegalovirus. In: Arvin A, Campadelli-Fiume G, Mocarski E, editors. Human herpesviruses: biology, therapy, and immunoprophylaxis. Cambridge: Cambridge University Press; 2007.
   Google Scholar
• Markham A, Faulds D. Ganciclovir. An update of its therapeutic use in cytomegalovirus infection. Drugs. 1994;48(3):455–484.
   PubMed Web of Science ®Google Scholar
• Frank KB, Chiou JF, Cheng YC. Interaction of herpes simplex virus-induced DNA polymerase with 9-(1,3-dihydroxy-2-propoxymethyl)guanine triphosphate. J Biol Chem. 1984;259(3):1566–1569.
   PubMed Web of Science ®Google Scholar
• Mar EC, Cheng YC, Huang ES. Effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine on human cytomegalovirus replication in vitro. Antimicrob Agents Chemother. 1983;24(4):518–521.
   PubMed Web of Science ®Google Scholar
• Tocci MJ, Livelli TJ, Perry HC, et al. Effects of the nucleoside analog 2ʹ-nor-2ʹ-deoxyguanosine on human cytomegalovirus replication. Antimicrob Agents Chemother. 1984;25(2):247–252.
   PubMed Web of Science ®Google Scholar
• Winston DJ, Wirin D, Shaked A, et al. Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients. Lancet. 1995;346(8967):69–74.
   PubMed Web of Science ®Google Scholar
• Singh N, Yu VL, Mieles L, et al. High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. A randomized trial. Ann Intern Med. 1994;120(5):375–381.
   PubMed Web of Science ®Google Scholar
• Paya CV, Wilson JA, Espy MJ, et al. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial. J Infect Dis. 2002;185(7):854–860.
   PubMed Web of Science ®Google Scholar
• Pescovitz MD, Rabkin J, Merion RM, et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother. 2000;44(10):2811–2815.
   PubMed Web of Science ®Google Scholar
• Singh N, Paterson DL, Gayowski T, et al. Cytomegalovirus antigenemia directed pre-emptive prophylaxis with oral versus I.V. ganciclovir for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, controlled trial. Transplantation. 2000;70(5):717–722.
   PubMed Web of Science ®Google Scholar
• Gane E, Saliba F, Valdecasas GJ, et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected]. Lancet. 1997;350(9093):1729–1733.
   PubMed Web of Science ®Google Scholar
• Humar A, Snydman D. Cytomegalovirus in solid organ transplant recipients. Am J Transplant. 2009;9(Suppl 4):S78–86.
   PubMed Web of Science ®Google Scholar
• Kotton CN, Kumar D, Caliendo AM, et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2013;96(4):333–360.
   PubMed Web of Science ®Google Scholar
• Asberg A, Humar A, Jardine AG, et al. Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am J Transplant. 2009;9(5):1205–1213.
   PubMed Web of Science ®Google Scholar
• Li F, Kenyon KW, Kirby KA, et al. Incidence and clinical features of ganciclovir-resistant cytomegalovirus disease in heart transplant recipients. Clin Infect Dis. 2007;45(4):439–447.
   PubMed Web of Science ®Google Scholar
• Limaye AP. Antiviral resistance in cytomegalovirus: an emerging problem in organ transplant recipients. Semin Respir Infect. 2002;17(4):265–273.
   PubMedGoogle Scholar
• Limaye AP. Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin Infect Dis. 2002;35(7):866–872.
   PubMed Web of Science ®Google Scholar
• Limaye AP, Corey L, Koelle DM, et al. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet. 2000;356(9230):645–649.
   PubMed Web of Science ®Google Scholar
• Limaye AP, Raghu G, Koelle DM, et al. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis. 2002;185(1):20–27.
   PubMed Web of Science ®Google Scholar
• Eid AJ, Arthurs SK, Deziel PJ, et al. Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes. Clin Transplant. 2008;22(2):162–170.
   PubMed Web of Science ®Google Scholar
• Razonable RR, Paya CV. Valganciclovir for the prevention and treatment of cytomegalovirus disease in immunocompromised hosts. Expert Rev Anti Infect Ther. 2004;2(1):27–41.
   PubMedGoogle Scholar
• Brown F, Banken L, Saywell K, et al. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers. Clin Pharmacokinet. 1999;37(2):167–176.
   PubMed Web of Science ®Google Scholar
• Wiltshire H, Hirankarn S, Farrell C, et al. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients. Clin Pharmacokinet. 2005;44(5):495–507.
   PubMed Web of Science ®Google Scholar
• Caldes A, Colom H, Armendariz Y, et al. Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus. Antimicrob Agents Chemother. 2009;53(11):4816–4824.
   PubMed Web of Science ®Google Scholar
• Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2004;4(4):611–620.
   PubMed Web of Science ®Google Scholar
• Kalil AC, Freifeld AG, Lyden ER, et al. Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacy. Plos One. 2009;4(5):e5512.
   PubMed Web of Science ®Google Scholar
• Kalil AC, Mindru C, Botha JF, et al. Risk of cytomegalovirus disease in high-risk liver transplant recipients on valganciclovir prophylaxis: a systematic review and meta-analysis. Liver Transpl. 2012;18(12):1440–1447.
   PubMed Web of Science ®Google Scholar
• Levitsky J, Singh N, Wagener MM, et al. A survey of CMV prevention strategies after liver transplantation. Am J Transplant. 2008;8(1):158–161.
   PubMed Web of Science ®Google Scholar
• Humar A, Limaye AP, Blumberg EA, et al. Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study. Transplantation. 2010;90(12):1427–1431.
   PubMed Web of Science ®Google Scholar
• Palmer SM, Limaye AP, Banks M, et al. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial. Ann Intern Med. 2010;152(12):761–769.
   PubMed Web of Science ®Google Scholar
• Finlen Copeland CA, Davis WA, Snyder LD, et al. Long-term efficacy and safety of 12 months of valganciclovir prophylaxis compared with 3 months after lung transplantation: a single-center, long-term follow-up analysis from a randomized, controlled cytomegalovirus prevention trial. J Heart Lung Transplant. 2011;30(9):990–996.
   PubMed Web of Science ®Google Scholar
• Boivin G, Goyette N, Farhan M, et al. Incidence of cytomegalovirus UL97 and UL54 amino acid substitutions detected after 100 or 200 days of valganciclovir prophylaxis. J Clin Virol. 2012;53(3):208–213.
   PubMed Web of Science ®Google Scholar
• Halim MA, Al-Otaibi T, Gheith O, et al. Efficacy and Safety of Low-Dose Versus Standard-Dose Valganciclovir for Prevention of Cytomegalovirus Disease in Intermediate-Risk Kidney Transplant Recipients. Exp Clin Transplant. 2016;5:526–534.
   Google Scholar
• Gabardi S, Asipenko N, Fleming J, et al. Evaluation of low- versus high-dose valganciclovir for prevention of cytomegalovirus disease in high-risk renal transplant recipients. Transplantation. 2015;99(7):1499–1505.
   PubMed Web of Science ®Google Scholar
• Kalil AC, Mindru C, Florescu DF. Effectiveness of valganciclovir 900 mg versus 450 mg for cytomegalovirus prophylaxis in transplantation: direct and indirect treatment comparison meta-analysis. Clin Infect Dis. 2011;52(3):313–321.
   PubMed Web of Science ®Google Scholar
• Julian KG, Shattahi E, Burg JE, et al. Low-dose valganciclovir for cytomegalovirus prophylaxis in heart transplant recipients. Transplant Proc. 2013;45(9):3414–3417.
   PubMed Web of Science ®Google Scholar
• Stevens DR, Sawinski D, Blumberg E, et al. Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis. Transpl Infect Dis. 2015;17(2):163–173.
   PubMed Web of Science ®Google Scholar
• Young PG, Rubin J, Angarone M, et al. Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients: a single-center retrospective cohort study. Transpl Infect Dis. 2016;18(3):390–395.
   PubMed Web of Science ®Google Scholar
• Asberg A, Humar A, Rollag H, et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2007;7(9):2106–2113.
   PubMed Web of Science ®Google Scholar
• Len O, Gavalda J, Aguado JM, et al. Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients. Clin Infect Dis. 2008;46(1):20–27.
   PubMed Web of Science ®Google Scholar
• Kim JM, Kwon CH, Joh JW, et al. Oral valganciclovir as a preemptive treatment for cytomegalovirus (CMV) infection in CMV-seropositive liver transplant recipients. Plos One. 2015;10(5):e0123554.
   PubMed Web of Science ®Google Scholar
• Mengelle C, Rostaing L, Weclawiak H, et al. Prophylaxis versus pre-emptive treatment for prevention of cytomegalovirus infection in CMV-seropositive orthotopic liver-transplant recipients. J Med Virol. 2015;87(5):836–844.
   PubMed Web of Science ®Google Scholar
• Togashi J, Sugawara Y, Hashimoto M, et al. Oral valganciclovir versus intravenous ganciclovir as preemptive treatment for cytomegalovirus infection after living donor liver transplantation: a randomized trial. Biosci Trends. 2011;5(5):217–222.
   PubMed Web of Science ®Google Scholar
• Razonable RR, Humar A. Cytomegalovirus in solid organ transplantation. Am J Transplant. 2013;13 Suppl 4:93–106.
   PubMed Web of Science ®Google Scholar
• Wagstaff AJ, Bryson HM. Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs. 1994;48(2):199–226.
   PubMed Web of Science ®Google Scholar
• Balfour HH Jr., Fletcher CV, Erice A, et al. Effect of foscarnet on quantities of cytomegalovirus and human immunodeficiency virus in blood of persons with AIDS. Antimicrob Agents Chemother. 1996;40(12):2721–2726.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Enger C, Forman M, et al. Incidence of foscarnet resistance and cidofovir resistance in patients treated for cytomegalovirus retinitis. The Cytomegalovirus Retinitis and Viral Resistance Study Group. Antimicrob Agents Chemother. 1998;42(9):2240–2244.
   PubMed Web of Science ®Google Scholar
• Balfour HH Jr., Benson C, Braun J, et al. Management of acyclovir-resistant herpes simplex and varicella-zoster virus infections. J Acquir Immune Defic Syndr. 1994;7(3):254–260.
   PubMed Web of Science ®Google Scholar
• Beaufils H, Deray G, Katlama C, et al. Foscarnet and crystals in glomerular capillary lumens. Lancet. 1990;336(8717):755.
   PubMed Web of Science ®Google Scholar
• Jacobson MA, Causey D, Polsky B, et al. A dose-ranging study of daily maintenance intravenous foscarnet therapy for cytomegalovirus retinitis in AIDS. J Infect Dis. 1993;168(2):444–448.
   PubMed Web of Science ®Google Scholar
• Lor E, Liu YQ. Neurologic sequelae associated with foscarnet therapy. Ann Pharmacother. 1994;28(9):1035–1037.
   PubMed Web of Science ®Google Scholar
• Lea AP, Bryson HM. Cidofovir. Drugs. 1996;52(2):225–230; discussion 231.
   PubMed Web of Science ®Google Scholar
• Cundy KC. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin Pharmacokinet. 1999;36(2):127–143.
   PubMed Web of Science ®Google Scholar
• Wolf DL, Rodriguez CA, Mucci M, et al. Pharmacokinetics and renal effects of cidofovir with a reduced dose of probenecid in HIV-infected patients with cytomegalovirus retinitis. J Clin Pharmacol. 2003;43(1):43–51.
   PubMed Web of Science ®Google Scholar
• Cherrington JM, Fuller MD, Lamy PD, et al. In vitro antiviral susceptibilities of isolates from cytomegalovirus retinitis patients receiving first- or second-line cidofovir therapy: relationship to clinical outcome. J Infect Dis. 1998;178(6):1821–1825.
   PubMed Web of Science ®Google Scholar
• Kazory A, Singapuri S, Wadhwa A, et al. Simultaneous development of Fanconi syndrome and acute renal failure associated with cidofovir. J Antimicrob Chemother. 2007;60(1):193–194.
   PubMed Web of Science ®Google Scholar
• Ambati J, Wynne KB, Angerame MC, et al. Anterior uveitis associated with intravenous cidofovir use in patients with cytomegalovirus retinitis. Br J Ophthalmol. 1999;83(10):1153–1158.
   PubMed Web of Science ®Google Scholar
• Tseng AL, Mortimer CB, Salit IE. Iritis associated with intravenous cidofovir. Ann Pharmacother. 1999;33(2):167–171.
   PubMed Web of Science ®Google Scholar
• Lu H, Thomas S. Maribavir (ViroPharma). Curr Opin Investig Drugs. 2004;5(8):898–906.
   PubMedGoogle Scholar
• Maribavir: 1263W94, Benzimidavir, GW 1263, GW 1263W94, VP41263. Drugs R D. 2007;8(3):188–192. PMID: 17472414.
   PubMedGoogle Scholar
• Biron KK, Harvey RJ, Chamberlain SC, et al. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob Agents Chemother. 2002;46(8):2365–2372.
   PubMed Web of Science ®Google Scholar
• Krosky PM, Baek MC, Coen DM. The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress. J Virol. 2003;77(2):905–914.
   PubMed Web of Science ®Google Scholar
• Williams SL, Hartline CB, Kushner NL, et al. In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses. Antimicrob Agents Chemother. 2003;47(7):2186–2192.
   PubMed Web of Science ®Google Scholar
• Koszalka GW, Johnson NW, Good SS, et al. Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob Agents Chemother. 2002;46(8):2373–2380.
   PubMed Web of Science ®Google Scholar
• Lalezari JP, Aberg JA, Wang LH, et al. Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding. Antimicrob Agents Chemother. 2002;46(9):2969–2976.
   PubMed Web of Science ®Google Scholar
• Winston DJ, Young JA, Pullarkat V, et al. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood. 2008;111(11):5403–5410.
   PubMed Web of Science ®Google Scholar
• Winston DJ, Saliba F, Blumberg E, et al. Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial. Am J Transplant. 2012;12(11):3021–3030.
   PubMed Web of Science ®Google Scholar
• Marty FM, Ljungman P, Papanicolaou GA, et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis. 2011;11(4):284–292.
   PubMed Web of Science ®Google Scholar
• Avery RK, Marty FM, Strasfeld L, et al. Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients. Transpl Infect Dis. 2010;12(6):489–496.
   PubMed Web of Science ®Google Scholar
• Trofe J, Pote L, Wade E, et al. Maribavir: a novel antiviral agent with activity against cytomegalovirus. Ann Pharmacother. 2008;42(10):1447–1457.
   PubMed Web of Science ®Google Scholar
• Painter W, Robertson A, Trost LC, et al. First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses. Antimicrob Agents Chemother. 2012;56(5):2726–2734.
   PubMed Web of Science ®Google Scholar
• Hostetler KY. Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art. Antiviral Res. 2009;82(2):A84–98.
   PubMed Web of Science ®Google Scholar
• Aldern KA, Ciesla SL, Winegarden KL, et al. Increased antiviral activity of 1-O-hexadecyloxypropyl-[2-(14)C]cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism. Mol Pharmacol. 2003;63(3):678–681.
   PubMed Web of Science ®Google Scholar
• Kern ER, Hartline C, Harden E, et al. Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir. Antimicrob Agents Chemother. 2002;46(4):991–995.
   PubMed Web of Science ®Google Scholar
• Ciesla SL, Trahan J, Wan WB, et al. Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. Antiviral Res. 2003;59(3):163–171.
   PubMed Web of Science ®Google Scholar
• Painter GR, Hostetler KY. Design and development of oral drugs for the prophylaxis and treatment of smallpox infection. Trends Biotechnol. 2004;22(8):423–427.
   PubMed Web of Science ®Google Scholar
• Quenelle DC, Lampert B, Collins DJ, et al. Efficacy of CMX001 against herpes simplex virus infections in mice and correlations with drug distribution studies. J Infect Dis. 2010;202(10):1492–1499.
   PubMed Web of Science ®Google Scholar
• Rinaldo CH, Gosert R, Bernhoff E, et al. 1-O-hexadecyloxypropyl cidofovir (CMX001) effectively inhibits polyomavirus BK replication in primary human renal tubular epithelial cells. Antimicrob Agents Chemother. 2010;54(11):4714–4722.
   PubMed Web of Science ®Google Scholar
• Randhawa P, Zemlicka J, Sauerbrei A, et al. Anti-BK virus activity of nucleoside analogs. Antimicrob Agents Chemother. 2008;52(4):1519–1521.
   PubMed Web of Science ®Google Scholar
• Randhawa P, Farasati NA, Shapiro R, et al. Ether lipid ester derivatives of cidofovir inhibit polyomavirus BK replication in vitro. Antimicrob Agents Chemother. 2006;50(4):1564–1566.
   PubMed Web of Science ®Google Scholar
• Hartline CB, Gustin KM, Wan WB, et al. Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: activity against adenovirus replication in vitro. J Infect Dis. 2005;191(3):396–399.
   PubMed Web of Science ®Google Scholar
• Quenelle DC, Collins DJ, Herrod BP, et al. Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice. Antimicrob Agents Chemother. 2007;51(11):3940–3947.
   PubMed Web of Science ®Google Scholar
• Rice AD, Adams MM, Lampert B, et al. Efficacy of CMX001 as a prophylactic and presymptomatic antiviral agent in New Zealand white rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans. Viruses. 2011;3(2):63–82.
   PubMed Web of Science ®Google Scholar
• Florescu DF, Pergam SA, Neely MN, et al. Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients. Biol Blood Marrow Transplant. 2012;18(5):731–738.
   PubMed Web of Science ®Google Scholar
• Beadle JR, Hartline C, Aldern KA, et al. Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro. Antimicrob Agents Chemother. 2002;46(8):2381–2386.
   PubMed Web of Science ®Google Scholar
• Kern ER, Collins DJ, Wan WB, et al. Oral treatment of murine cytomegalovirus infections with ether lipid esters of cidofovir. Antimicrob Agents Chemother. 2004;48(9):3516–3522.
   PubMed Web of Science ®Google Scholar
• Bidanset DJ, Beadle JR, Wan WB, et al. Oral activity of ether lipid ester prodrugs of cidofovir against experimental human cytomegalovirus infection. J Infect Dis. 2004;190(3):499–503.
   PubMed Web of Science ®Google Scholar
• Marty FM, Winston DJ, Rowley SD, et al. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med. 2013;369(13):1227–1236.
   PubMed Web of Science ®Google Scholar
• Goldner T, Hempel C, Ruebsamen-Schaeff H, et al. Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. Antimicrob Agents Chemother. 2014;58(1):610–613.
   PubMed Web of Science ®Google Scholar
• Goldner T, Hewlett G, Ettischer N, et al. The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J Virol. 2011;85(20):10884–10893.
   PubMed Web of Science ®Google Scholar
• Goldner T, Zimmermann H, Lischka P. Phenotypic characterization of two naturally occurring human Cytomegalovirus sequence polymorphisms located in a distinct region of ORF UL56 known to be involved in in vitro resistance to letermovir. Antiviral Res. 2015;116:48–50.
   PubMed Web of Science ®Google Scholar
• Kropeit D. 2010. Phase I safety and PK data of the novel anti-HCMV terminase inhibitor AIC246. Abstract 1994 presented at the 50th Interscience Conference of Antimicrobial Agents and Chemotherapy; Boston, MA.
   Google Scholar
• Marschall M, Stamminger T, Urban A, et al. In vitro evaluation of the activities of the novel anticytomegalovirus compound AIC246 (letermovir) against herpesviruses and other human pathogenic viruses. Antimicrob Agents Chemother. 2012;56(2):1135–1137.
   PubMed Web of Science ®Google Scholar
• Chemaly RF, Ullmann AJ, Stoelben S, et al. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med. 2014;370(19):1781–1789.
   PubMed Web of Science ®Google Scholar
• Stoelben S, Arns W, Renders L, et al. Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study. Transpl Int. 2014;27(1):77–86.
   PubMed Web of Science ®Google Scholar
• Kaul DR, Stoelben S, Cober E, et al. First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246. Am J Transplant. 2011;11(5):1079–1084.
   PubMed Web of Science ®Google Scholar
• Melendez DP, Razonable RR. Letermovir and inhibitors of the terminase complex: a promising new class of investigational antiviral drugs against human cytomegalovirus. Infect Drug Resist. 2015;8:269–277.
   PubMed Web of Science ®Google Scholar
• Kern ER, Kushner NL, Hartline CB, et al. In vitro activity and mechanism of action of methylenecyclopropane analogs of nucleosides against herpesvirus replication. Antimicrob Agents Chemother. 2005;49(3):1039–1045.
   PubMed Web of Science ®Google Scholar
• Kern ER, Bidanset DJ, Hartline CB, et al. Oral activity of a methylenecyclopropane analog, cyclopropavir, in animal models for cytomegalovirus infections. Antimicrob Agents Chemother. 2004;48(12):4745–4753.
   PubMed Web of Science ®Google Scholar
• Abele G, Karlstrom A, Harmenberg J, et al. Inhibiting effect of (RS)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine on varicella-zoster virus replication in cell culture. Antimicrob Agents Chemother. 1987;31(1):76–80.
   PubMed Web of Science ®Google Scholar
• Ng TI, Shi Y, Huffaker HJ, et al. Selection and characterization of varicella-zoster virus variants resistant to (R)-9-[4-hydroxy-2-(hydroxymethy)butyl]guanine. Antimicrob Agents Chemother. 2001;45(6):1629–1636.
   PubMed Web of Science ®Google Scholar
• Tyring SK, Plunkett S, Scribner AR, et al. Valomaciclovir versus valacyclovir for the treatment of acute herpes zoster in immunocompetent adults: a randomized, double-blind, active-controlled trial. J Med Virol. 2012;84(8):1224–1232.
   PubMed Web of Science ®Google Scholar
• McGuigan C, Pathirana RN, Migliore M, et al. Preclinical development of bicyclic nucleoside analogues as potent and selective inhibitors of varicella zoster virus. J Antimicrob Chemother. 2007;60(6):1316–1330.
   PubMed Web of Science ®Google Scholar
• Balzarini J, Sienaert R, Liekens S, et al. Lack of susceptibility of bicyclic nucleoside analogs, highly potent inhibitors of varicella-zoster virus, to the catabolic action of thymidine phosphorylase and dihydropyrimidine dehydrogenase. Mol Pharmacol. 2002;61(5):1140–1145.
   PubMed Web of Science ®Google Scholar
• Pentikis HS, Matson M, Atiee G, et al. Pharmacokinetics and safety of FV-100, a novel oral anti-herpes zoster nucleoside analogue, administered in single and multiple doses to healthy young adult and elderly adult volunteers. Antimicrob Agents Chemother. 2011;55(6):2847–2854.
   PubMed Web of Science ®Google Scholar
• Tyring S, Wald A, Zadeikis N, et al. ASP2151 for the treatment of genital herpes: a randomized, double-blind, placebo- and valacyclovir-controlled, dose-finding study. J Infect Dis. 2012;205(7):1100–1110.
   PubMed Web of Science ®Google Scholar
• Wald A, Corey L, Timmler B, et al. Helicase-primase inhibitor pritelivir for HSV-2 infection. N Engl J Med. 2014;370(3):201–210.
   PubMed Web of Science ®Google Scholar
• Manuel O, Husain S, Kumar D, et al. Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. Clin Infect Dis. 2013;56(6):817–824.
   PubMed Web of Science ®Google Scholar
• Melendez D, Razonable RR. Immune-based monitoring for cytomegalovirus infection in solid organ transplantation: is it ready for clinical primetime? Expert Rev Clin Immunol. 2014;10(9):1213–1227.
   PubMed Web of Science ®Google Scholar
• Razonable RR. Management strategies for cytomegalovirus infection and disease in solid organ transplant recipients. Infect Dis Clin North Am. 2013;27(2):317–342.
   PubMed Web of Science ®Google Scholar